论文部分内容阅读
目的了解医院临床分离的554株肠球菌属的耐药性。方法菌株鉴定及药敏检测采用法国生物梅里埃公司的VITEK60分析仪。结果554株肠球菌属中粪肠球菌361株(65.2%),屎肠球菌143株(25.8%),鹑鸡肠球菌22株(4.0%),鸟肠球菌18株(3.2%),其他肠球菌10株(1.8%);粪肠球菌对青霉素和氨苄西林的耐药率较低分别为5.3%和1.1%,是临床首选的一类药,但屎肠球菌对青霉素和氨苄西林的耐药率均已达74.0%,应慎用,而宜首选喹奴普汀/达福普汀和利奈唑烷,治疗由粪肠球菌和屎肠球菌以外的肠球菌引起的感染,宜首选利奈唑烷。结论临床治疗肠球菌属感染在针对其多药耐药性的同时,还应根据肠球菌属耐药性存在种间差异的特点来选择相应的治疗方案,以免耐药趋势的蔓延。
Objective To understand the clinical drug resistance of 554 enterococci isolated in the hospital. Methods Strain identification and drug susceptibility testing using the French biomedical company VITEK60 analyzer. Results Among the 554 enterococci, 361 (65.2%) were Enterococcus faecalis, 143 (25.8%) were Enterococcus faecium, 22 (4.0%) were Enterococcus faecalis and 18 10 strains of E.coli (1.8%); Enterococcus faecalis and penicillin and ampicillin resistance rates of 5.3% and 1.1%, respectively, is the first choice of clinical medicine, but Enterococcus faecium penicillin and ampicillin resistance The rate has reached 74.0%, should be used with caution, and should be the preferred choice of quinupristin / dalfopristin and linezolid, Enterococcus faecalis and Enterococcus other than enterococci infection, preferred linezolid . Conclusions The clinical treatment of Enterococcus infections in response to its multidrug resistance at the same time, should also be based on the characteristics of Enterococcus resistance exist between species to choose the appropriate treatment to avoid the spread of drug resistance trends.